Ratings by Piper Sandler (Yasmeen Rahimi)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 4/16/2024 | Varonis Systems | VRNS | Maintain | Overweight (N/A) |
|
Details | ||
| 4/16/2024 | Verona Pharma | VRNA | Maintain | Overweight (N/A) |
|
Details | ||
| 4/4/2024 | Unicycive Therapeutics | UNCY | New Coverage | Overweight (N/A) |
1.38 (0.97) |
-29.71% | Details | |
| 3/7/2024 | Edgewise Therapeutics | EWTX | New Coverage | Overweight (N/A) |
16.97 (15.94) |
-6.07% | Details | |
| 3/4/2024 | Savara | SVRA | Maintain | Overweight (N/A) |
|
Details | ||
| 2/16/2024 | AnaptysBio | ANAB | New Coverage | Overweight (N/A) |
22.29 (18.87) |
-15.34% | Details | |
| 2/13/2024 | CymaBay Therapeutic | CBAY | Downgrade | Neutral (Overweight) |
32.21 (32.48) |
0.84% | Details | |
| 2/5/2024 | Soleno Therapeutics Inc. | SLNO | New Coverage | Overweight (N/A) |
46.92 (37.34) |
-20.42% | Details | |
| 1/16/2024 | NewAmsterdam Pharma Co NV | NAMS | New Coverage | Overweight (N/A) |
17.11 (21.44) |
25.31% | Details | |
| 12/18/2023 | Structure Therapeutics | GPCR | Maintain | Overweight (N/A) |
|
Details | ||
| 12/14/2023 | Reneo Pharmaceuticals | RPHM | Downgrade | Neutral (Overweight) |
7.75 (1.65) |
-78.71% | Details | |
| 11/14/2023 | Design Therapeutics Inc | DSGN | Downgrade | Neutral (Overweight) |
2.05 (3.76) |
83.41% | Details | |
| 11/10/2023 | Korro Bio Inc. | KRRO | New Coverage | Overweight (N/A) |
41.40 (58.53) |
41.38% | Details | |
| 11/6/2023 | CymaBay Therapeutic | CBAY | Maintain | Overweight (N/A) |
|
Details | ||
| 10/26/2023 | Structure Therapeutics | GPCR | Maintain | Overweight (N/A) |
|
Details | ||
| 10/25/2023 | Tourmaline Bio | TRML | New Coverage | Overweight (N/A) |
9.46 (16.00) |
69.13% | Details | |
| 10/24/2023 | Immunovant | IMVT | Maintain | Overweight (N/A) |
|
Details | ||
| 8/8/2023 | Sagimet Biosciences Inc | SGMT | New Coverage | Overweight (N/A) |
16.09 (3.92) |
-75.64% | Details | |
| 7/27/2023 | Structure Therapeutics | GPCR | New Coverage | Overweight (N/A) |
35.14 (38.98) |
10.93% | Details | |
| 5/30/2023 | Acelyrin Inc | SLRN | New Coverage | Overweight (N/A) |
19.42 (4.24) |
-78.17% | Details | |
| 4/24/2023 | Crinetics | CRNX | New Coverage | Overweight (N/A) |
17.22 (42.29) |
145.59% | Details | |
| 4/18/2023 | Prometheus Biosciences Inc | RXDX | Downgrade | Neutral (Overweight) |
114.01 (199.92) |
75.35% | Details | |
| 3/31/2023 | Immunovant | IMVT | New Coverage | Overweight (N/A) |
15.71 (27.75) |
76.64% | Details | |
| 3/7/2023 | Allakos Inc. | ALLK | New Coverage | Overweight (N/A) |
5.80 (1.01) |
-82.59% | Details | |
| 3/6/2023 | Chinook Therapeutics | KDNY | New Coverage | Overweight (N/A) |
22.81 (40.39) |
77.07% | Details | |
| 2/22/2023 | Cincor Pharma Inc | CINC | Maintain | Overweight (N/A) |
|
Details | ||
| 1/27/2023 | Prothena Corp | PRTA | New Coverage | Overweight (N/A) |
55.25 (20.56) |
-62.79% | Details | |
| 12/19/2022 | Madrigal Pharmaceuticals | MDGL | Maintain | Overweight (N/A) |
|
Details | ||
| 9/12/2022 | Ventyx Biosciences Inc | VTYX | Maintain | Overweight (N/A) |
|
Details | ||
| 8/29/2022 | Prometheus Biosciences Inc | RXDX | Maintain | Overweight (N/A) |
|
Details | ||
| 8/26/2022 | Verona Pharma | VRNA | New Coverage | Overweight (N/A) |
10.59 (15.31) |
44.57% | Details | |
| 8/22/2022 | Cincor Pharma Inc | CINC | New Coverage | Overweight (N/A) |
35.02 (29.06) |
-17.02% | Details | |
| 8/19/2022 | Ventyx Biosciences Inc | VTYX | Maintain | Overweight (N/A) |
|
Details | ||
| 8/12/2022 | Lexicon Pharmaceuticals | LXRX | New Coverage | Overweight (N/A) |
2.78 (1.54) |
-44.6% | Details | |
| 6/10/2022 | Cytokinetics | CYTK | Maintain | Overweight (N/A) |
|
Details | ||
| 6/10/2022 | Prometheus Biosciences Inc | RXDX | New Coverage | Overweight (N/A) |
29.00 (199.92) |
589.38% | Details | |
| 6/7/2022 | Intercept Pharmaceuticals | ICPT | Maintain | Overweight (N/A) |
|
Details | ||
| 5/6/2022 | Protagonist Therapeutics | PTGX | Maintain | Overweight (N/A) |
|
Details | ||
| 3/29/2022 | Ventyx Biosciences Inc | VTYX | Maintain | Overweight (N/A) |
|
Details | ||
| 3/22/2022 | Sage Therapeutics | SAGE | Maintain | Overweight (N/A) |
|
Details | ||
| 11/15/2021 | Ventyx Biosciences Inc | VTYX | New Coverage | Overweight (N/A) |
22.97 (4.06) |
-82.32% | Details | |
| 10/12/2021 | Protagonist Therapeutics | PTGX | Maintain | Overweight (N/A) |
|
Details | ||
| 10/5/2021 | Cytokinetics | CYTK | Maintain | Overweight (N/A) |
|
Details | ||
| 9/22/2021 | Mirum Pharamceuticals | MIRM | Maintain | Overweight (N/A) |
|
Details | ||
| 9/21/2021 | Gossamer Bio Inc. | GOSS | New Coverage | Overweight (N/A) |
10.52 (0.67) |
-93.63% | Details | |
| 9/8/2021 | Altimmune | ALT | Maintain | Overweight (N/A) |
|
Details | ||
| 8/24/2021 | Tenaya Therapeutics Inc | TNYA | New Coverage | Overweight (N/A) |
22.67 (4.22) |
-81.39% | Details | |
| 8/6/2021 | NGM Biopharmaceuticals | NGM | Maintain | Overweight (N/A) |
|
Details | ||
| 7/30/2021 | Protagonist Therapeutics | PTGX | Maintain | Overweight (N/A) |
|
Details | ||
| 6/11/2021 | Vaxart Inc. | VXRT | New Coverage | Overweight (N/A) |
7.64 (0.66) |
-91.36% | Details | |
| 6/9/2021 | Intercept Pharmaceuticals | ICPT | Maintain | Overweight (N/A) |
|
Details | ||
| 6/2/2021 | Liminal BioSciences, Inc. | LMNL | Downgrade | Neutral (Overweight) |
4.42 (8.50) |
92.31% | Details | |
| 5/21/2021 | Protagonist Therapeutics | PTGX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/7/2021 | Madrigal Pharmaceuticals | MDGL | Maintain | Overweight (N/A) |
|
Details | ||
| 5/4/2021 | Reneo Pharmaceuticals | RPHM | New Coverage | Overweight (N/A) |
14.40 (1.65) |
-88.54% | Details | |
| 4/20/2021 | Design Therapeutics Inc | DSGN | New Coverage | Overweight (N/A) |
23.50 (3.76) |
-84% | Details | |
| 4/7/2021 | Sage Therapeutics | SAGE | New Coverage | Overweight (N/A) |
77.89 (13.58) |
-82.57% | Details | |
| 3/16/2021 | Savara | SVRA | New Coverage | Overweight (N/A) |
1.57 (4.45) |
183.44% | Details | |
| 3/9/2021 | CymaBay Therapeutic | CBAY | Maintain | Overweight (N/A) |
|
Details | ||
| 3/1/2021 | Albireo Pharma | ALBO | Maintain | Overweight (N/A) |
|
Details | ||
| 12/21/2020 | Liminal BioSciences, Inc. | LMNL | New Coverage | Overweight (N/A) |
4.09 (8.50) |
107.82% | Details | |
| 12/16/2020 | Protagonist Therapeutics | PTGX | New Coverage | Overweight (N/A) |
20.92 (24.66) |
17.88% | Details | |
| 9/28/2020 | Mirum Pharamceuticals | MIRM | Maintain | Overweight (N/A) |
|
Details | ||
| 9/8/2020 | Albireo Pharma | ALBO | Maintain | Overweight (N/A) |
|
Details | ||
| 9/4/2020 | Amarin Corporation | AMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 8/26/2020 | Arcturus Therapeutics | ARCT | New Coverage | Overweight (N/A) |
54.24 (26.17) |
-51.75% | Details | |
| 8/26/2020 | Enanta Pharmaceuticals | ENTA | New Coverage | Overweight (N/A) |
49.02 (12.48) |
-74.54% | Details | |
| 8/26/2020 | Immunic Inc. | IMUX | New Coverage | Overweight (N/A) |
15.29 (1.26) |
-91.76% | Details | |
| 8/26/2020 | Lumos Pharma | LUMO | New Coverage | Overweight (N/A) |
14.96 (2.76) |
-81.55% | Details | |
| 8/25/2020 | Amarin Corporation | AMRN | New Coverage | Overweight (N/A) |
6.79 (0.86) |
-87.33% | Details | |
| 7/31/2020 | 89bio Inc. | ETNB | New Coverage | Overweight (N/A) |
28.77 (8.25) |
-71.32% | Details | |
| 7/31/2020 | Mirum Pharamceuticals | MIRM | New Coverage | Overweight (N/A) |
20.26 (24.49) |
20.88% | Details | |
| 7/31/2020 | 89bio Inc. | ETNB | New Coverage | Overweight (N/A) |
28.77 (8.25) |
-71.32% | Details | |
| 7/31/2020 | CymaBay Therapeutic | CBAY | New Coverage | Overweight (N/A) |
3.53 (32.48) |
820.11% | Details | |
| 7/31/2020 | Axcella Health Inc. | AXLA | New Coverage | Overweight (N/A) |
4.51 (4.58) |
1.55% | Details | |
| 7/31/2020 | Albireo Pharma | ALBO | New Coverage | Overweight (N/A) |
25.55 (44.15) |
72.8% | Details | |
| 7/31/2020 | NGM Biopharmaceuticals | NGM | New Coverage | Overweight (N/A) |
18.43 (1.54) |
-91.64% | Details | |
| 7/31/2020 | Altimmune | ALT | New Coverage | Overweight (N/A) |
22.52 (7.20) |
-68.03% | Details | |
| 7/31/2020 | Madrigal Pharmaceuticals | MDGL | New Coverage | Overweight (N/A) |
103.30 (194.38) |
88.17% | Details | |
| 7/31/2020 | Intercept Pharmaceuticals | ICPT | New Coverage | Overweight (N/A) |
45.60 (19.00) |
-58.33% | Details |
